A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
Ontology highlight
ABSTRACT: This study is to define the safety profile and to determine the Maximal tolerated dose regimen and preliminary efficacy of AbGn-107 administered every 14 days (Q2W regimen) or 28 days (Q4W regimen) in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal, pancreatic or biliary cancer.
DISEASE(S): Adenocarcinoma,Biliary Cancer,Biliary Tract Neoplasms,Gastric Cancer,Colorectal Cancer,Pancreatic Cancer,Cancer
PROVIDER: 2225595 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA